Abstract
The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
Highlights
Intravenous (i.v.) iron is often used in the management of iron deficiency anemia in patients with nondialysis-dependent chronic kidney disease (CKD)
Concerns persist regarding hypersensitivity and oxidative stress.[1]. These arise owing to earlier experience with older i.v. iron compounds suggesting possible nephrotoxicity owing to increased proteinuria, a phenomenon credited both directly and indirectly to oxidative damage.[2]
Baseline serum creatinine was significantly lower in the FDI group (158 vs. 201 mmol/L, P 1⁄4 0.03), estimated glomerular filtration rate calculated using both creatinine and cystatin C were not significantly different between the 2 groups
Summary
Intravenous (i.v.) iron is often used in the management of iron deficiency anemia in patients with nondialysis-dependent chronic kidney disease (CKD). As there is increasing real-world evidence on the utility and costeffectiveness of high-dose treatment with thirdgeneration i.v. iron preparations in populations with non–dialysis-dependent CKD,S1 it is important to explore whether any negative renal impact exists after their administration. The study was primarily designed to evaluate the impact of i.v. iron (FDI) at a high dose (1000 mg) in patients with non–dialysisdependent CKD and iron deficiency but not anemia on 6minute walk test, as an objective measure of functional status.[4] This was performed to establish whether similar positive effects as those exhibited in patients with heart failure exist in this population. We report on the renal-associated secondary objectives evaluating the renal effect of high-dose FDI in this patient group (Supplementary Methods)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call